Cell & Gene Therapy

Discover new pharma manufacturing solutions in developing robust and scalable manufacturing processes to produce consistent, high-quality cell and gene therapies.

Cell and gene therapy (CGT) has emerged as a groundbreaking field in pharmaceutical manufacturing due to its potential to revolutionize the treatment of various diseases. Our CGT Circuit features a variety of content from industry thought leaders, consultants, regulatory agencies and industry suppliers to increase your knowledge and understanding of the latest developments in cell and gene therapy manufacturing including addressing manufacturing hurdles.

Resources

Page

Editorial Articles

  • Beyond the Plate: Where Biofluorescent Particle Counting Can Reduce Errors and Strengthen Contamination Control

    The goal is not to eliminate plates. It is to reduce the number of reasons to open or intervene in the isolator. By supplementing traditional environmental monitoring with real-time BFPC, manufacturers can preserve the value of growth-based methods while reducing avoidable interventions—and, consequently, the number of investigations triggered by the monitoring process itself.
  • Aligning Environmental Monitoring Expectations with Scientific Realities

    Considering the advances in aseptic processing and their effectiveness in eliminating the primary sources of contamination (i.e., human activity), it is not our intent to entirely disparage the value of monitoring. Environmental monitoring has some value in trend analysis within an overall contamination control strategy. However, it is not a control mechanism.
  • Aseptic Fill Finish: Bridging the Gap Between Upstream Precision and Downstream Excellence

    As the sterile fill finish market continues to grow, the role of specialized drug delivery CDMO partnerships must shift from baseline execution to long-term future-proofing. Experienced partners add the highest value by anticipating how shifting global regulatory expectations and future market demands will impact a molecule years after its initial validation.
  • Typical and Representative, Part 1

    As technology in endotoxins and pyrogens testing changes, and as the basic research advances our understanding of pyrogenicity, fifty-year-old assumptions and decisions should be revisited, if not challenged. Given that it is neither typical nor representative of potential contaminants, is the current calibrant still an appropriate analyte for endotoxins and pyrogens testing?
  • Packaging Is Tough

    The lesson here isn’t that packaging is bad. It’s that packaging is where all the science, formulation work, and quality control finally meets a real person standing in a real kitchen. If the patient can’t get the product out in one piece, all of that great work ends up in crumbs on the counter.
  • Focused Ultrasound’s Therapeutic Potential for Blood-Brain Barrier Opening

    Neurological disease accounts for a large share of the global disease burden. CNS drug development, however, remains unusually difficult. One major reason is anatomical, not pharmacological: even a compound with strong target biology has little therapeutic value if it cannot reach the relevant brain tissue at sufficient concentration.